• Premature Stimulation Expands Atrial Slow Conduction

  2026-09-13

  This PLOS ONE study shows that premature stimulation enlarges pre-existing slow-conduction regions in atria remodeled by persistent atrial fibrillation, rather than primarily creating new regions. Its optical-mapping framework links pacing-dependent conduction behavior to arrhythmogenic substrate and offers a practical approach for quantifying spatially dynamic conduction abnormalities.

• Azilsartan (TAK-536) Workflow for RAS Models

  2026-09-12

  Azilsartan (TAK-536) provides a selective AT1-receptor perturbation strategy for connecting renin–angiotensin signaling with inflammatory and reactive glial phenotypes. This practical guide translates the gastrodin astrocyte–microglia study into concentration-response, conditioned-medium, readout, and troubleshooting workflows.

• Palmitic acid: Protocol and QC Guide

  2026-09-11

  Palmitic acid (hexadecanoic acid, SKU N2456) provides a characterized saturated long-chain fatty acid for controlled lipid supplementation, palmitoylation-related experiments, and metabolic disorder research. It is suitable for nonaqueous preparation and prompt use, but not for aqueous-only workflows or long-term storage as a solution.

• Neuritin, ER Stress, and NF-κB After SAH

  2026-09-11

  This Brain Research study identifies three endoplasmic-reticulum-stress inflammatory branches that connect subarachnoid hemorrhage to neuroinflammation and neuronal apoptosis during early brain injury. Its central finding is that neuritin overexpression suppresses IRE1α-, PERK-, and ATF6-associated NF-κB signaling, providing a mechanistic explanation for neuritin-mediated neuroprotection.

• IEM 1460: Reliable AMPA Blockade Workflows

  2026-09-10

  This scenario-driven guide explains how IEM 1460 (SKU B6811) can support AMPA receptor inhibition assays, excitotoxicity experiments, and neuroprotection workflows. It connects product-backed handling information with practical controls while distinguishing selective AMPA blockade from evidence involving dual AMPA/NMDA antagonism.

• KR-12: Mechanism, Assays, and Translational Design

  2026-09-10

  KR-12 human antimicrobial peptide research is best understood through the relationship between membrane activity, biofilm assay design, and salt-form handling. This evidence-focused guide explains how to interpret KR-12 results without conflating bactericidal, antibiofilm, LPS-neutralizing, or mammalian-cell endpoints.

• A 83-01 in Corneal Fibrosis Assays

  2026-09-09

  A 83-01 is an ALK-5 inhibitor that enables mechanistic dissection of TGF-β/SMAD3 signaling in corneal fibrosis. This article translates recent LMCD1 findings into practical assay-design, dosing, control, and interpretation strategies.

• HotStart 2X Green qPCR Master Mix Workflow

  2026-09-09

  Build more defensible SYBR Green assays for gene expression, RNA-seq validation, and nucleic acid quantification with a hot-start workflow designed to limit nonspecific amplification. The approach also shows how qPCR can support mRNA nanovaccine studies without confusing assay validation with therapeutic efficacy.

• (R,S)-Anatabine: Aβ Assay Strategy

  2026-09-08

  Explore how (R,S)-Anatabine connects APP processing, BACE-1 regulation, and NF-κB signaling in Alzheimer’s disease research. This guide adds a cross-disciplinary assay-design perspective based on mechanistic lessons from epidermal homeostasis research.

• Acifran: HCAR2/HCAR3 Signaling Guide

  2026-09-08

  Acifran, also known as (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a research agonist used to study HCAR2/GPR109A and HCAR3/GPR109B signaling. Cryo-EM evidence places Acifran in both HCAR3-Gi and HCAR2-Gi complexes, supporting its use in receptor recognition and lipid metabolism research.

• MALAT1–miR-125b/STAT3 Control of PCT in Sepsis

  2026-09-07

  The reference study identifies a MALAT1–miR-125b–STAT3 regulatory axis that increases procalcitonin expression in sepsis-related inflammatory models. Its combination of patient samples, LPS-stimulated U937 cells, localization analysis, target validation, and rescue experiments provides a mechanistic framework for interpreting PCT regulation while also highlighting limits in translating cell-model findings to clinical practice.

• Concanamycin A: Reliable V-ATPase Assays

  2026-09-07

  This scenario-driven guide explains how Concanamycin A (SKU A8633) can clarify viability, apoptosis, trafficking, and invasion results in cancer biology research. It connects mechanism, protocol design, data interpretation, and practical product-selection criteria for more defensible cell-based assays.

• Lactate Workflows for Metabolic–Immune Research

  2026-09-05

  Use L-lactate as both a quantitative metabolic readout and a controlled signaling input in glycolysis, hypoxia, mitochondrial, and tumor–immune experiments. This workflow emphasizes compartment-aware sampling, matched controls, and mechanistic validation around the NAT1–ENO1–lactate–PD-L1 axis.

• LG 101506: A Mechanism-First RXR Guide

  2026-09-04

  Explore LG 101506 as an RXR modulator through a mechanism-first framework linking nuclear receptor assays with checkpoint biology. Learn how the RBMS1–B4GALT1–PD-L1 study can inform controls, endpoints, and interpretation without overstating evidence.

• GSK J4 HCl: JMJD3 Inhibition Workflows

  2026-09-04

  GSK J4 HCl enables cell-based testing of JMJD3-dependent H3K27 demethylation across inflammatory, decidual, and tumor models. This practical guide connects chromatin occupancy with cytokine output, highlights controls, and provides troubleshooting strategies for more causal epigenetic regulation research.

8110 records 6/541 page Previous Next First page 上5页 678910 下5页 Last page